Table 2.

Results of the 2020 and 2021 editions of the survey, by pillar

Survey year	2020*		2021**
Pillars	EJP RD£	EU13¥	EJP RD£	EU13¥
RD research funding (P1)
National calls	44%	UKN	59%	33%
Joint transnational calls	56%	17%	46%	33%
Investments to share knowledge	44%	33%	46%	33%
Other public funding/networking	81%	67%	68%	56%
Private funding initiatives	56%	33%	48%	11%
Access to data, tools and services (P2)
Advisory body of national experts
General	50%	50%	52%	56%
Specific for RD	13%	1%	8%	1%
Support data repositories and tools for RD in NP/NS
General support	81%	50%	78%	56%
FAIR data	31%	NR	50%	NR
Holistic approaches RD diagnosis and treatment	72%	50%	81%	67%
Initiatives other than NP/NS
Public investment	50%	17%	44%	22%
Private funding	38%	17%	48%	12%
FAIR data	25%	17%	44%	11%
Holistic approaches RD diagnosis and treatment	NR	33%	44%	45%
Capacity-building and empowerment (P3)
Promotion/support of RD trainings by NP/NS
All trainings	75%	67%	78%	67%
Empowerment of patients	83%	67%	72%	56%
Registries	42%	50%	61%	56%
Online education courses	42%	50%	39%	44%
Data management	33%	33%	44%	33%
Standards and quality of data (clinical and lab)	33%	67%	39%	56%
Biobanks	22%	17%	28%	22%
Data quality	22%	33%	22%	22%
FAIR data	NR	NR	11%	NR
Initiatives other than NP/NS (All trainings)	75%	NR	56%	NR
Accelerating research translation (P4)
Rapid translation of research results	50%	17%	48%	33%
Innovative methodologies for CT	56%	17%	61%	11%
Other initiatives than the NP/NS	38%	17%	36%	NR

CT clinical trial, NP national plan, NR not reported, NS national strategy, UKN unknown (four countries had negative answer and two “I do not know”) *21 countries (7 EU13); **27 countries (10 EU13); ^£ EJP RD partners including EU and associated partners; ^¥ Only EU13 countries